Nebulizer

Encore Healthcare Announces Staggering Results in New Nexus TeleRespiratory Care Pilot Using Data to Predict when Oxygen/Nebulizer Patients Need Non-Invasive Ventilation (NIV) Before Hospitalizations Happen

Friday, June 11, 2021 - 1:32pm

LIVINGSTON, Tenn., June 11, 2021 /PRNewswire/ --Encore Healthcare announces staggering results from their new oxygen and nebulizer management Nexus TeleRespiratory Care model.

Key Points: 
  • LIVINGSTON, Tenn., June 11, 2021 /PRNewswire/ --Encore Healthcare announces staggering results from their new oxygen and nebulizer management Nexus TeleRespiratory Care model.
  • In the initial pilot with a national HME provider Encore identified 12.5% of patients on oxygen/nebulizers needed additional services including medications, NIV and High Frequency Chest Wall Oscillation (HFCWO).
  • These results are an example of how data can drive better patient outcomes and revenue to HME providers at the same time.
  • The Nexus platform aligns HME respiratory providers across traditional boundaries while increasing provider productivity and clinical outcomes with their Ventilator/High-Risk COPD patients.

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

Thursday, June 10, 2021 - 7:00am

Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.

Key Points: 
  • Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.
  • Since its inception in 2014, Nuance Pharma has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain and iron deficiency anemia.

Verona Pharma to Present at Jefferies Virtual Healthcare Conference

Tuesday, May 25, 2021 - 7:00am

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Key Points: 
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.
  • All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Friday, May 14, 2021 - 1:05pm

These equity awards were granted pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employee\xe2\x80\x99s acceptance of employment with the Company.\nThe options have an exercise price of $1.62 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date.

Key Points: 
  • These equity awards were granted pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employee\xe2\x80\x99s acceptance of employment with the Company.\nThe options have an exercise price of $1.62 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date.
  • The RSUs vest in full on the two-year anniversary of May 3, 2021, subject to the employee\xe2\x80\x99s continued employment on such vesting date.\nSavara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.
  • Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
  • Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

Global Nebulizers (Pneumatic, Ultrasonic, Mesh) Market Report 2021: COVID-19 Impacts, Implications and Growth to 2025 & 2030 - ResearchAndMarkets.com

Wednesday, May 12, 2021 - 1:32pm

b'The "Nebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nNebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030 covers this critical market and the impact on it from the COVID-19 virus.

Key Points: 
  • b'The "Nebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nNebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030 covers this critical market and the impact on it from the COVID-19 virus.
  • The market is expected to reach $1.55 billion in 2025 at a CAGR of 10.5%.\nThe nebulizer devices market consists of sales of nebulizers used in respiratory care for patients with respiratory diseases including asthma, cystic fibrosis and COPD.
  • There has been an increased use of albuterol inhalers in hospitals for Covid-19 and suspected Covid-19 patients to help with respiratory issues.
  • Rise in geriatric population is anticipated to propel the nebulizer market growth.\n'

Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference

Tuesday, May 4, 2021 - 7:00am

Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (\xe2\x80\x9cCFTR\xe2\x80\x9d), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.

Key Points: 
  • Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (\xe2\x80\x9cCFTR\xe2\x80\x9d), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (\xe2\x80\x9cEnsifentrine as a Novel inHAled Nebulized COPD thErapy\xe2\x80\x9d) for COPD maintenance treatment.
  • Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (\xe2\x80\x9cDPI\xe2\x80\x9d) and pressurized metered-dose inhaler (\xe2\x80\x9cpMDI\xe2\x80\x9d).
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.\n"

HCmed Signs a Global Development Agreement with Global Biotechnology Leader CSL Behring

Tuesday, May 4, 2021 - 3:00am

b'TAIPEI, May 3, 2021 /PRNewswire/ -- HCmed today announces the start of a strategic partnership with global biotherapeutics leader CSL Behring to collaboratively develop CSL Behring\'s plasma derived immunoglobulin administered via HCmed\'s new generation vibrating-mesh nebulizing device (CSL787).

Key Points: 
  • b'TAIPEI, May 3, 2021 /PRNewswire/ -- HCmed today announces the start of a strategic partnership with global biotherapeutics leader CSL Behring to collaboratively develop CSL Behring\'s plasma derived immunoglobulin administered via HCmed\'s new generation vibrating-mesh nebulizing device (CSL787).
  • Under the terms of the agreement, CSL Behring will have sole responsibility for the development and commercialization of the combination product, with HCmed leading the development of the customized nebulizing device specifically optimized for CSL Behring\'s formulation.
  • HCmed will receive an upfront payment and device and development milestones.
  • "\nFounded in 2014, HCmed Innovations Co., Ltd. focuses on the development of drug-device combination products based on its vibrating mesh nebulizer technology.

HCmed Signs a Global Development Agreement with Global Biotechnology Leader CSL Behring

Tuesday, May 4, 2021 - 3:00am

b'TAIPEI, May 3, 2021 /PRNewswire/ -- HCmed today announces the start of a strategic partnership with global biotherapeutics leader CSL Behring to collaboratively develop CSL Behring\'s plasma derived immunoglobulin administered via HCmed\'s new generation vibrating-mesh nebulizing device (CSL787).

Key Points: 
  • b'TAIPEI, May 3, 2021 /PRNewswire/ -- HCmed today announces the start of a strategic partnership with global biotherapeutics leader CSL Behring to collaboratively develop CSL Behring\'s plasma derived immunoglobulin administered via HCmed\'s new generation vibrating-mesh nebulizing device (CSL787).
  • Under the terms of the agreement, CSL Behring will have sole responsibility for the development and commercialization of the combination product, with HCmed leading the development of the customized nebulizing device specifically optimized for CSL Behring\'s formulation.
  • HCmed will receive an upfront payment and device and development milestones.
  • "\nFounded in 2014, HCmed Innovations Co., Ltd. focuses on the development of drug-device combination products based on its vibrating mesh nebulizer technology.

Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update

Thursday, April 29, 2021 - 7:00am

b"Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Key Points: 
  • b"Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (\xe2\x80\x9cEnsifentrine as a Novel inHAled Nebulized COPD thErapy\xe2\x80\x9d) for COPD maintenance treatment.
  • Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (\xe2\x80\x9cDPI\xe2\x80\x9d) and pressurized metered-dose inhaler (\xe2\x80\x9cpMDI\xe2\x80\x9d).
  • All employees are working remotely and all business travel has been restricted.\nThis press release contains forward-looking statements.

Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International Journal of Chronic Obstructive Pulmonary Disease

Tuesday, April 27, 2021 - 7:00am

Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (\xe2\x80\x9cCFTR\xe2\x80\x9d), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.

Key Points: 
  • Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (\xe2\x80\x9cCFTR\xe2\x80\x9d), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (\xe2\x80\x9cEnsifentrine as a Novel inHAled Nebulized COPD thErapy\xe2\x80\x9d) for COPD maintenance treatment.
  • Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (\xe2\x80\x9cDPI\xe2\x80\x9d) and pressurized metered-dose inhaler (\xe2\x80\x9cpMDI\xe2\x80\x9d).
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.\n"